Soy and soy isoflavones in prostate cancer: a systematic review and meta‐analysis of randomized controlled trials

@article{Die2014SoyAS,
  title={Soy and soy isoflavones in prostate cancer: a systematic review and meta‐analysis of randomized controlled trials},
  author={M. Diana Die and Kerry Martin Bone and Scott G. Williams and Marie Pirotta},
  journal={BJU International},
  year={2014},
  volume={113}
}
To evaluate the evidence from randomized controlled trials (RCTs) on the efficacy and safety of soy/isoflavones in men with prostate cancer (PCa) or with a clinically identified risk of PCa. 

Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials

To evaluate the evidence from randomised trials for the efficacy and safety of phytotherapeutic interventions in the management of biochemically recurrent (BCR) prostate cancer, indicated by

Dietary supplements and prostate cancer prevention

The authors take a critical look at the evidence for supplements in prostate cancer and find that, in general, the evidence is wanting.

Synergistic Effects of Dietary Natural Products as Anti-Prostate Cancer Agents

This review is to describe synergistic effects of various combinations of dietary natural products including curcumin, quercetin, soybean isoflavones, silibinin, and EGCG that have potential for the

Soy protein supplementation in men following radical prostatectomy: a 2-year randomized, placebo-controlled clinical trial.

Exploratory analysis suggests that equol production status of subjects on soy may modify effects of soy on body weight and possibly blood pressure, and this study was a secondary analysis of body weight,Blood pressure, thyroid hormones, iron status, and clinical chemistry in a 2-y trial of soy protein supplementation in middle-aged to older men.

Androgen receptor and soy isoflavones in prostate cancer ( Review )

A detailed overview of the anticancer potential of soy isoflavones (genistein, daidzein and glycitein), as mediated by their effect on AR, is provided.

Randomized, Placebo-Controlled Six-Month Intervention Study of Soy Protein Isolate in Men with Biochemical Recurrence after Radical Prostatectomy: A Pilot Study

Although this study is too small to draw a definitive conclusion on the effect of soy protein on PSA in men with biochemical failure, the null finding is consistent with the results of virtually all reports of soy and soy isoflavones in the literature.

Effect of S-equol and Soy Isoflavones on Heart and Brain

Evidence from observational studies and short-term RCTs suggests that S-equol is anti-atherogenic and improves arterial stiffness and may prevent CHD and cognitive impairment/dementia.

Chemoprevention in Prostate Cancer: Current Perspective and Future Directions.

The modulation of inflammation is one of the most promising targets for chemoprevention of prostate cancer and the role of 5-α-reductase inhibitors has been well investigated and shown to decrease the risk of prostatecancer.
...

References

SHOWING 1-10 OF 49 REFERENCES

The specific role of isoflavones in reducing prostate cancer risk

To evaluate the effectiveness of supplementing a group of early stage prostate cancer patients, with 60 mg of soy isoflavones in producing a change in hormonal and proliferative risk parameters that

Meta‐analysis of soy food and risk of prostate cancer in men

Results of the analysis showed that consumption of soy food was associated with a lower risk of prostate cancer in men.

Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis.

Consuming soy foods is associated with a reduction in prostate cancer risk in men and this protection may be associated with the type and quantity of soy foods consumed.

Prostate Cancer Chemoprevention Study: An investigative randomized control study using purified isoflavones in men with rising prostate‐specific antigen

The value of is oflavone for prostate cancer risk reduction is supported, and a large‐scale phase III randomized study of isoflavone tablets in men with different hereditary factors and living environments is warranted.

An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels.

The clinical evidence is sufficiently encouraging to justify considering additional Phase II and III clinical trials investigating the efficacy of soy isoflavones in different populations of prostate cancer patients alone and in combination with other treatments.

A Phase II Randomized, Placebo-Controlled Clinical Trial of Purified Isoflavones in Modulating Steroid Hormones in Men Diagnosed With Localized Prostate Cancer

Increasing plasma isoflavones failed to produce a corresponding modulation of serum steroid hormone levels in men with localized prostate cancer and the need to explore other potential mechanisms by which prolonged and consistent purified is oflavone consumption may modulate prostate cancer risk is established.

Safety of Purified Isoflavones in Men With Clinically Localized Prostate Cancer

A continuous, divided-dose administration of 80 mg/day of purified isoflavones at amounts that exceeded normal American dietary intakes significantly increased plasma is oflavones in the isOflavone-treated group compared to placebo and produced no clinical toxicity.

Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy.

The results identify a safe dose of purified isoflavones for future clinical trials and establish the need for further definitive, well-powered trials to examine the role of is oflavones in prostate carcinogenesis.

Soy protein isolate increases urinary estrogens and the ratio of 2:16alpha-hydroxyestrone in men at high risk of prostate cancer.

Increased urinary E2 excretion and 2:16 OH‐E1 ratio in men consuming soy protein isolate are consistent with studies in women and suggest that soy consumption may be beneficial in men at high risk of progressing to advanced prostate cancer.